The Unified Patent Court has become a significant development for every IP and pharma expert in the world, regulatory bodies on both sides of the Atlantic are sanctioning pharma companies for anti-competitive behaviour, EU national courts are increasing their referrals to the ECJ for answers and clarifications on a wide spectrum of topics, new European alternative IP courts are being created and emerging markets keep altering their IP laws and procedures. These changes will force everyone within the biotech and pharma field to re-think and adjust their patent litigation strategies.Winfried Tilmann (right), who is of Counsel in Hogan Lovells' Dusseldorf office, a well-known figure in European patent litigation circles and the author of "The compromise on the uniform protection for EU patents" (see abstract here). Winfried is gearing up for a spot of positive thinking about the UPC, which has continued to receive a lukewarm reception in many quarters. He says:
"This conference, as regards the Unified Patent Court (UPC), comes at the right time for businesses preparing for the transitional period of the new Court, especially deciding on the question whether to use or not to use the opt-out-provision of the UPC Agreement in order to avoid a revocation action being started against their European patents before the UPC the effect of which would cover the entire territory of the contracting states".If you're thinking of attending, programme and registration details can be found here. There's a 15% discount off the conference price to IPKat readers (and their friends on PatLit ...) who quote the discount code 630KAT.